▲ +41.99% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $217.25, with a high forecast of $288.00 and a low forecast of $130.00. The average price target represents a 41.99% upside from the last price of $153.00.
The current consensus among 11 contributing investment analysts is to buy stock in iRhythm Technologies. This Buy consensus rating has held steady for over two years.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was founded in 2006 and is headquartered in San Francisco, California.